CytoDel has developed a platform to specifically deliver therapeutic antibodies to the neuronal cytoplasm, enabling access to intraneuronal targets not accessible by conventional antibodies. The platform is based on recombinant atoxic derivatives of botulinum neurotoxin (BoT, aka Botox), which retain BoT’s unique neuronal trafficking but are 106-fold less toxic. Cyto-111 is a first-in-class BoT-based Antibody Fusion Protein, which delivers a nanobody that inactivates the intraneuronal protease causing botulism. Cyto-111 is effective when conventional antibodies are ineffective because they cannot access the neuronal cytoplasm. The safety and effectiveness of Cyto-111 has been demonstrated in three species, including non-human primates. Ongoing work is addressing chronic pain and neurodegenerative disease by targeting the intraneuronal pathways driving pathology, and taking advantage of retrograde transport along neuronal circuits as a privileged pathway for delivery to the CNS.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
Cyto-111 & Cyto-014
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
